Remember meForgot password?
    Log in with Twitter
Press Release

Diabetic Neuropathy - Pipeline Review, H1 2018; New Report Launched has announced the addition of “Diabetic Neuropathy - Pipeline Review, H1 2018” research report to their website

This press release was orginally distributed by SBWire

Bangalore, India -- (SBWIRE) -- 06/12/2018 -- Diabetic Neuropathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights
Diabetic Neuropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 3, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 103 pages "Diabetic Neuropathy - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Diabetic Neuropathy - Overview, Diabetic Neuropathy - Therapeutics Development, Diabetic Neuropathy - Therapeutics Assessment, Diabetic Neuropathy - Companies Involved in Therapeutics Development, Diabetic Neuropathy - Drug Profiles, Diabetic Neuropathy - Dormant Projects, Appendix. This report Covered Companies - Achelios Therapeutics Inc, Angelini Group, Arena Pharmaceuticals Inc, Bristol-Myers Squibb Co, Commence Bio Inc, Grifols SA, Grunenthal GmbH, Immune Pharmaceuticals Inc, Kineta Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, NovaLead Pharma Pvt Ltd, Novaremed Ltd, Omeros Corp, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, Sphaera Pharma Pte Ltd, ViroMed Co Ltd.

For more information Visit at:

Find all Pharma and Healthcare Reports at -

Related Reports;

Diabetic Retinopathy - Pipeline Review, H1 2018 - Visit at -

Diabetic Foot Ulcers - Pipeline Review, H1 2018 - Visit at -

About is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

For more information on this press release visit:

Media Relations Contact

Sudeep Chakravarty
Director - Operations
Telephone: 302-703-9904
Email: Click to Email Sudeep Chakravarty

Latest News
Top News